BiotechTube

BEAM-101

Phase 1/2Active
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sickle Cell Disease

Conditions

Sickle Cell Disease

Trial Timeline

Aug 30, 2022 → Feb 1, 2028

NCT ID
NCT05456880

About BEAM-101

BEAM-101 is a phase 1/2 stage product being developed by Beam Therapeutics for Sickle Cell Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05456880. Target conditions include Sickle Cell Disease.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05456880Phase 1/2Active

Competing Products

20 competing products in Sickle Cell Disease

See all competitors
ProductCompanyStageHype Score
Prasugrel + PlaceboDaiichi SankyoPhase 3
77
PrasugrelDaiichi SankyoPhase 1
33
Prasugrel + PlaceboDaiichi SankyoPhase 2
52
PrasugrelDaiichi SankyoPhase 2
52
LexiscanAstellas PharmaPhase 1
33
Placebo + DalteparinEisaiPhase 2
52
tadalafil + placeboEli LillyPhase 2
52
Prasugrel (clinical formulation) + Prasugrel (Orally Disintegrating Tablet [ODT])Eli LillyPhase 1
33
Lidocaine Iv + PlaceboJohnson & JohnsonPhase 2
52
ICA-17043Johnson & JohnsonPhase 3
77
TicagrelorAstraZenecaPhase 1
33
Ticagrelor granule + Ticagrelor pediatric tablets + Ticagrelor pediatric tablets suspended in water + Ticagrelor immediate release (IR) tablets (Commercial tablet)AstraZenecaPhase 1
33
Ticagrelor + PlaceboAstraZenecaPhase 2
52
Ticagrelor + PlaceboAstraZenecaPhase 3
77
Brilinta + PlaceboAstraZenecaPhase 3
77
Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2bAstraZenecaPhase 2
52
vorinostatMerckPhase 2
52
Crizanlizumab + PlaceboNovartisPhase 3
77
Crizanlizuamb + Standard of CareNovartisPhase 2
52
CrizanlizumabNovartisApproved
85

Other Products from Beam Therapeutics

BEAM-201Phase 1/2
36
BEAM-301: Single dose of BEAM-301 administered by IVPhase 1/2
36
BEAM-302Phase 1/2
36
BEAM-103 + Placebo ComparatorPhase 1
28
Allogeneic anti-CD7 CAR-T cells (BEAM-201)Phase 1
28